Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia‐Manero, Jean‐Pierre J. Issa, Hagop M. Kantarjian et al.|Blood|2006Cited by 468
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateElias Jabbour, Jörge E. Cortes, Hagop M. Kantarjian et al.|Leukemia|2006Cited by 387
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Elias Jabbour et al.|The Lancet Haematology|2020Cited by 330
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Michael J. Keating, Deborah A. Thomas et al.|Blood|2003Cited by 254
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian et al.|Haematologica|2015Cited by 252